Selpercatinib Receives Traditional FDA Approval for RET Fusion–Positive Solid Tumors

The FDA has granted traditional approval to selpercatinib for the treatment of advanced or metastatic RET fusion-positive solid tumors in patients aged 2 and older who have received prior systemic treatment. This regulatory action provides a new therapeutic option for a specific subset of cancer patients.